GlassScriptPhysician profile
Chaim J Bernstein
NPI 1548262348
$185,907.92
in general payments reported to CMS, 2019-2025
28 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $32K · 2021: $27K · 2022: $28K · 2023: $13K · 2024: $13K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $8,875 · Honoraria: $8,000 · Travel and Lodging: $506 · Education: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,709.02 |
| Food and Beverage | $8,874.55 |
| Honoraria | $8,000.00 |
| Travel and Lodging | $506.16 |
| Education | $497.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $74,478.12 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Mallinckrodt Hospital Products INC. | $44,456.31 | 2020-2025 | Acthar |
| Sunovion Pharmaceuticals INC. | $20,578.61 | 2019-2021 | |
| Insmed, INC. | $13,618.08 | 2019-2025 | Arikayce, Brinsupri |
| Verona Pharma, INC. | $9,434.86 | 2025 | Ohtuvayre |
| Mallinckrodt Enterprises LLC | $7,315.74 | 2019 | |
| Glaxosmithkline, LLC. | $4,505.17 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $3,458.47 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Baxter Healthcare | $2,043.31 | 2023-2024 | Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $1,751.32 | 2019-2024 | (Ak6) Vest Therapy |
| Advanced Respiratory, INC | $1,136.15 | 2019-2021 | |
| Mylan Specialty L.P. | $586.77 | 2019-2024 | Yupelri |
| Medtronic, INC. | $541.41 | 2024-2025 | Endurant Iis, Valiant Captivia |
| Regeneron Healthcare Solutions, INC. | $516.78 | 2019-2025 | Dupixent |
| Genzyme Corporation | $481.33 | 2019-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $251.05 | 2021-2025 | Tezspire |
| Electromed, INC. | $218.18 | 2019-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $178.68 | 2019-2023 | Uptravi, Opsumit |
| Viatris Specialty LLC | $104.34 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $94.12 | 2020-2022 | |
| Genentech USA, INC. | $39.36 | 2019 | |
| United Therapeutics Corporation | $32.12 | 2023-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $18.64 | 2023 | Aralast |
| Ani Pharmaceuticals, INC. | $16.29 | 2023 | Purified Cortrophin Gel |
| Novo Nordisk INC | $15.85 | 2021 | |
| Merck Sharp & Dohme LLC | $14.74 | 2023 | |
| Paratek Pharmaceuticals, INC. | $14.36 | 2024 | Nuzyra |
| 3b Medical, INC. | $7.76 | 2024 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaim Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.